APO Research
Talk to an analyst

APO RESEARCH · REPORT

Drug Carcinogenicity Testing

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Drug Carcinogenicity Testing Market Analysis and Forecast 2026-2032

4 March 2026199 pages

Choose your research edition.

Industry ResearchDrug Carcinogenicity Testing Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Drug Carcinogenicity Testing Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Drug Carcinogenicity Testing Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drug Carcinogenicity Testing Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Drug Carcinogenicity Testing Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Drug Carcinogenicity Testing market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Drug Carcinogenicity Testing is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Drug Carcinogenicity Testing is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Drug Carcinogenicity Testing is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Drug Carcinogenicity Testing is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Drug Carcinogenicity Testing include Inotiv, Charles River Laboratories, Creative Biolabs, Vivotecnia, Aurigene Pharmaceutical Services, Lhasa Limited, Wako Pure Chemical Industries, Ichor Life Sciences and Frontage Labs, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Drug Carcinogenicity Testing, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Drug Carcinogenicity Testing, also provides the revenue of main regions and countries. Of the upcoming market potential for Drug Carcinogenicity Testing, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Drug Carcinogenicity Testing revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Drug Carcinogenicity Testing market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Drug Carcinogenicity Testing revenue, projected growth trends, production technology, application and end-user industry.

Drug Carcinogenicity Testing Segment by Company

Inotiv

Charles River Laboratories

Creative Biolabs

Vivotecnia

Aurigene Pharmaceutical Services

Lhasa Limited

Wako Pure Chemical Industries

Ichor Life Sciences

Frontage Labs

WuXi AppTec

Nanjing Enhancer

Drug Carcinogenicity Testing Segment by Type

Transgenic Mouse Assay

Mouse Bioassay

Drug Carcinogenicity Testing Segment by Application

Medicine

Pharmaceutical

Drug Carcinogenicity Testing Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drug Carcinogenicity Testing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drug Carcinogenicity Testing and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drug Carcinogenicity Testing.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Drug Carcinogenicity Testing in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Drug Carcinogenicity Testing company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Drug Carcinogenicity Testing revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Drug Carcinogenicity Testing Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Transgenic Mouse Assay Major Player Table 3. Mouse Bioassay Major Player Table 4. Global Drug Carcinogenicity Testing Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Medicine Major Player Table 6. Pharmaceutical Major Player Table 7. Drug Carcinogenicity Testing Industry Trends Table 8. Drug Carcinogenicity Testing Industry Drivers Table 9. Drug Carcinogenicity Testing Industry Opportunities and Challenges Table 10. Drug Carcinogenicity Testing Industry Restraints Table 11. Global Drug Carcinogenicity Testing Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 12. Global Drug Carcinogenicity Testing Market Size by Region (2021-2026) & (US$ Million) Table 13. Global Drug Carcinogenicity Testing Market Share by Region (2021-2026) Table 14. Global Drug Carcinogenicity Testing Market Size by Region (2027-2032) & (US$ Million) Table 15. Global Drug Carcinogenicity Testing Market Share by Region (2027-2032) Table 16. Global Drug Carcinogenicity Testing Revenue by Players (US$ Million) & (2021-2026) Table 17. Global Drug Carcinogenicity Testing Revenue Market Share by Players (2021-2026) Table 18. Global Drug Carcinogenicity Testing Key Players Ranking, 2024 VS 2025 VS 2026 Table 19. Global Drug Carcinogenicity Testing Key Players Headquarters & Area Served Table 20. Global Drug Carcinogenicity Testing Players, Product Type & Application Table 21. Global Drug Carcinogenicity Testing Players Establishment Date Table 22. Global Players Market Concentration Ratio (CR5 and HHI) Table 23. Global Drug Carcinogenicity Testing by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 24. Global Drug Carcinogenicity Testing Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Drug Carcinogenicity Testing Revenue by Type (2021-2026) & (US$ Million) Table 26. Global Drug Carcinogenicity Testing Revenue by Type (2027-2032) & (US$ Million) Table 27. Global Drug Carcinogenicity Testing Revenue Market Share by Type (2021-2026) Table 28. Global Drug Carcinogenicity Testing Revenue Market Share by Type (2027-2032) Table 29. Global Drug Carcinogenicity Testing Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Drug Carcinogenicity Testing Revenue by Application (2021-2026) & (US$ Million) Table 31. Global Drug Carcinogenicity Testing Revenue by Application (2027-2032) & (US$ Million) Table 32. Global Drug Carcinogenicity Testing Revenue Market Share by Application (2021-2026) Table 33. Global Drug Carcinogenicity Testing Revenue Market Share by Application (2027-2032) Table 34. Inotiv Company Information Table 35. Inotiv Business Overview Table 36. Inotiv Drug Carcinogenicity Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 37. Inotiv Drug Carcinogenicity Testing Product Portfolio Table 38. Inotiv Recent Development Table 39. Charles River Laboratories Company Information Table 40. Charles River Laboratories Business Overview Table 41. Charles River Laboratories Drug Carcinogenicity Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Charles River Laboratories Drug Carcinogenicity Testing Product Portfolio Table 43. Charles River Laboratories Recent Development Table 44. Creative Biolabs Company Information Table 45. Creative Biolabs Business Overview Table 46. Creative Biolabs Drug Carcinogenicity Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Creative Biolabs Drug Carcinogenicity Testing Product Portfolio Table 48. Creative Biolabs Recent Development Table 49. Vivotecnia Company Information Table 50. Vivotecnia Business Overview Table 51. Vivotecnia Drug Carcinogenicity Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. Vivotecnia Drug Carcinogenicity Testing Product Portfolio Table 53. Vivotecnia Recent Development Table 54. Aurigene Pharmaceutical Services Company Information Table 55. Aurigene Pharmaceutical Services Business Overview Table 56. Aurigene Pharmaceutical Services Drug Carcinogenicity Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. Aurigene Pharmaceutical Services Drug Carcinogenicity Testing Product Portfolio Table 58. Aurigene Pharmaceutical Services Recent Development Table 59. Lhasa Limited Company Information Table 60. Lhasa Limited Business Overview Table 61. Lhasa Limited Drug Carcinogenicity Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Lhasa Limited Drug Carcinogenicity Testing Product Portfolio Table 63. Lhasa Limited Recent Development Table 64. Wako Pure Chemical Industries Company Information Table 65. Wako Pure Chemical Industries Business Overview Table 66. Wako Pure Chemical Industries Drug Carcinogenicity Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. Wako Pure Chemical Industries Drug Carcinogenicity Testing Product Portfolio Table 68. Wako Pure Chemical Industries Recent Development Table 69. Ichor Life Sciences Company Information Table 70. Ichor Life Sciences Business Overview Table 71. Ichor Life Sciences Drug Carcinogenicity Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. Ichor Life Sciences Drug Carcinogenicity Testing Product Portfolio Table 73. Ichor Life Sciences Recent Development Table 74. Frontage Labs Company Information Table 75. Frontage Labs Business Overview Table 76. Frontage Labs Drug Carcinogenicity Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. Frontage Labs Drug Carcinogenicity Testing Product Portfolio Table 78. Frontage Labs Recent Development Table 79. WuXi AppTec Company Information Table 80. WuXi AppTec Business Overview Table 81. WuXi AppTec Drug Carcinogenicity Testing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. WuXi AppTec Drug Carcinogenicity Testing Product Portfolio Table 83. WuXi AppTec Recent Development Table 84. Nanjing Enhancer Company Information Table 85. Nanjing Enhancer Business Overview Table 86. Nanjing Enhancer Drug Carcinogenicity Testing Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 87. Nanjing Enhancer Drug Carcinogenicity Testing Product Portfolio Table 88. Nanjing Enhancer Recent Development Table 89. North America Drug Carcinogenicity Testing Revenue by Type (2021-2026) & (US$ Million) Table 90. North America Drug Carcinogenicity Testing Revenue by Type (2027-2032) & (US$ Million) Table 91. North America Drug Carcinogenicity Testing Revenue by Application (2021-2026) & (US$ Million) Table 92. North America Drug Carcinogenicity Testing Revenue by Application (2027-2032) & (US$ Million) Table 93. North America Drug Carcinogenicity Testing Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 94. North America Drug Carcinogenicity Testing Revenue by Country (2021-2026) & (US$ Million) Table 95. North America Drug Carcinogenicity Testing Revenue by Country (US$ Million) & (2027-2032) Table 96. Europe Drug Carcinogenicity Testing Revenue by Type (2021-2026) & (US$ Million) Table 97. Europe Drug Carcinogenicity Testing Revenue by Type (2027-2032) & (US$ Million) Table 98. Europe Drug Carcinogenicity Testing Revenue by Application (2021-2026) & (US$ Million) Table 99. Europe Drug Carcinogenicity Testing Revenue by Application (2027-2032) & (US$ Million) Table 100. Europe Drug Carcinogenicity Testing Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 101. Europe Drug Carcinogenicity Testing Revenue by Country (2021-2026) & (US$ Million) Table 102. Europe Drug Carcinogenicity Testing Revenue by Country (US$ Million) & (2027-2032) Table 103. China Drug Carcinogenicity Testing Revenue by Type (2021-2026) & (US$ Million) Table 104. China Drug Carcinogenicity Testing Revenue by Type (2027-2032) & (US$ Million) Table 105. China Drug Carcinogenicity Testing Revenue by Application (2021-2026) & (US$ Million) Table 106. China Drug Carcinogenicity Testing Revenue by Application (2027-2032) & (US$ Million) Table 107. Asia Drug Carcinogenicity Testing Revenue by Type (2021-2026) & (US$ Million) Table 108. Asia Drug Carcinogenicity Testing Revenue by Type (2027-2032) & (US$ Million) Table 109. Asia Drug Carcinogenicity Testing Revenue by Application (2021-2026) & (US$ Million) Table 110. Asia Drug Carcinogenicity Testing Revenue by Application (2027-2032) & (US$ Million) Table 111. Asia Drug Carcinogenicity Testing Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 112. Asia Drug Carcinogenicity Testing Revenue by Region (US$ Million) & (2021-2026) Table 113. Asia Drug Carcinogenicity Testing Revenue by Region (US$ Million) & (2027-2032) Table 114. SAMEA Drug Carcinogenicity Testing Revenue by Type (2021-2026) & (US$ Million) Table 115. SAMEA Drug Carcinogenicity Testing Revenue by Type (2027-2032) & (US$ Million) Table 116. SAMEA Drug Carcinogenicity Testing Revenue by Application (2021-2026) & (US$ Million) Table 117. SAMEA Drug Carcinogenicity Testing Revenue by Application (2027-2032) & (US$ Million) Table 118. SAMEA Drug Carcinogenicity Testing Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 119. SAMEA Drug Carcinogenicity Testing Revenue by Country (2021-2026) & (US$ Million) Table 120. SAMEA Drug Carcinogenicity Testing Revenue by Country (US$ Million) & (2027-2032) Table 121. Research Programs/Design for This Report Table 122. Authors List of This Report Table 123. Secondary Sources Table 124. Primary Sources List of Figures Figure 1. Drug Carcinogenicity Testing Image Figure 2. Global Drug Carcinogenicity Testing Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drug Carcinogenicity Testing Market Size Share 2021 VS 2025 VS 2032 Figure 4. Transgenic Mouse Assay Image Figure 5. Mouse Bioassay Image Figure 6. Global Drug Carcinogenicity Testing Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Drug Carcinogenicity Testing Market Size Share 2021 VS 2025 VS 2032 Figure 8. Medicine Image Figure 9. Pharmaceutical Image Figure 10. Global Drug Carcinogenicity Testing Market Size (US$ Million) & (2021-2032) Figure 11. Global Drug Carcinogenicity Testing Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Drug Carcinogenicity Testing Market Share by Region: 2021 VS 2025 VS 2032 Figure 13. Global Drug Carcinogenicity Testing Players Revenue Share Top 10 and Top 5 in 2025 Figure 14. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 15. Global Drug Carcinogenicity Testing Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Drug Carcinogenicity Testing Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Drug Carcinogenicity Testing Revenue Market Share by Type (2021-2032) Figure 18. Global Drug Carcinogenicity Testing Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Drug Carcinogenicity Testing Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 20. Global Drug Carcinogenicity Testing Revenue Market Share by Application (2021-2032) Figure 21. North America Drug Carcinogenicity Testing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 22. North America Drug Carcinogenicity Testing Revenue Share by Type (2021-2032) Figure 23. North America Drug Carcinogenicity Testing Revenue Share by Application (2021-2032) Figure 24. North America Drug Carcinogenicity Testing Revenue Share by Country (2021-2032) Figure 25. United States Drug Carcinogenicity Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 26. Canada Drug Carcinogenicity Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Mexico Drug Carcinogenicity Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Europe Drug Carcinogenicity Testing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 29. Europe Drug Carcinogenicity Testing Revenue Share by Type (2021-2032) Figure 30. Europe Drug Carcinogenicity Testing Revenue Share by Application (2021-2032) Figure 31. Europe Drug Carcinogenicity Testing Revenue Share by Country (2021-2032) Figure 32. Germany Drug Carcinogenicity Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. France Drug Carcinogenicity Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. U.K. Drug Carcinogenicity Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. Italy Drug Carcinogenicity Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Spain Drug Carcinogenicity Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Russia Drug Carcinogenicity Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Netherlands Drug Carcinogenicity Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Nordic Countries Drug Carcinogenicity Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. China Drug Carcinogenicity Testing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 41. China Drug Carcinogenicity Testing Revenue Share by Type (2021-2032) Figure 42. China Drug Carcinogenicity Testing Revenue Share by Application (2021-2032) Figure 43. Asia Drug Carcinogenicity Testing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. Asia Drug Carcinogenicity Testing Revenue Share by Type (2021-2032) Figure 45. Asia Drug Carcinogenicity Testing Revenue Share by Application (2021-2032) Figure 46. Asia Drug Carcinogenicity Testing Revenue Share by Region (2021-2032) Figure 47. Japan Drug Carcinogenicity Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 48. South Korea Drug Carcinogenicity Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. India Drug Carcinogenicity Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. Australia Drug Carcinogenicity Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Taiwan Drug Carcinogenicity Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Southeast Asia Drug Carcinogenicity Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. SAMEA Drug Carcinogenicity Testing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 54. SAMEA Drug Carcinogenicity Testing Revenue Share by Type (2021-2032) Figure 55. SAMEA Drug Carcinogenicity Testing Revenue Share by Application (2021-2032) Figure 56. SAMEA Drug Carcinogenicity Testing Revenue Share by Country (2021-2032) Figure 57. Brazil Drug Carcinogenicity Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Argentina Drug Carcinogenicity Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Chile Drug Carcinogenicity Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Colombia Drug Carcinogenicity Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Peru Drug Carcinogenicity Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Saudi Arabia Drug Carcinogenicity Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Israel Drug Carcinogenicity Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. UAE Drug Carcinogenicity Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Turkey Drug Carcinogenicity Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Iran Drug Carcinogenicity Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Egypt Drug Carcinogenicity Testing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Years Considered Figure 69. Research Process Figure 70. Key Executives Interviewed

Scope & coverage.

Types
  • Transgenic Mouse Assay
  • Mouse Bioassay
Applications
  • Medicine
  • Pharmaceutical
Companies covered
  • Inotiv
  • Charles River Laboratories
  • Creative Biolabs
  • Vivotecnia
  • Aurigene Pharmaceutical Services
  • Lhasa Limited
  • Wako Pure Chemical Industries
  • Ichor Life Sciences
  • Frontage Labs
  • WuXi AppTec
  • Nanjing Enhancer

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Drug Carcinogenicity Testing Market by Type
  3. 1.2.1 Global Drug Carcinogenicity Testing Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Transgenic Mouse Assay
  5. 1.2.3 Mouse Bioassay
  6. 1.3 Drug Carcinogenicity Testing Market by Application
  7. 1.3.1 Global Drug Carcinogenicity Testing Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Medicine
  9. 1.3.3 Pharmaceutical
  10. 1.4 Assumptions and Limitations
  11. 1.5 Study Goals and Objectives
2 Drug Carcinogenicity Testing Market Dynamics
  1. 2.1 Drug Carcinogenicity Testing Industry Trends
  2. 2.2 Drug Carcinogenicity Testing Industry Drivers
  3. 2.3 Drug Carcinogenicity Testing Industry Opportunities and Challenges
  4. 2.4 Drug Carcinogenicity Testing Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Drug Carcinogenicity Testing Market Perspective (2021-2032)
  2. 3.2 Global Drug Carcinogenicity Testing Growth Trends by Region
  3. 3.2.1 Global Drug Carcinogenicity Testing Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Drug Carcinogenicity Testing Market Size by Region (2021-2026)
  5. 3.2.3 Global Drug Carcinogenicity Testing Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Drug Carcinogenicity Testing Revenue by Players
  2. 4.1.1 Global Drug Carcinogenicity Testing Revenue by Players (2021-2026)
  3. 4.1.2 Global Drug Carcinogenicity Testing Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Drug Carcinogenicity Testing Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Drug Carcinogenicity Testing Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Drug Carcinogenicity Testing Key Players Headquarters & Area Served
  7. 4.4 Global Drug Carcinogenicity Testing Players, Product Type & Application
  8. 4.5 Global Drug Carcinogenicity Testing Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Drug Carcinogenicity Testing Market CR5 and HHI
  11. 4.6.3 2025 Drug Carcinogenicity Testing Tier 1, Tier 2, and Tier 3
5 Drug Carcinogenicity Testing Market Size by Type
  1. 5.1 Global Drug Carcinogenicity Testing Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Drug Carcinogenicity Testing Revenue by Type (2021-2032)
  3. 5.3 Global Drug Carcinogenicity Testing Revenue Market Share by Type (2021-2032)
6 Drug Carcinogenicity Testing Market Size by Application
  1. 6.1 Global Drug Carcinogenicity Testing Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Drug Carcinogenicity Testing Revenue by Application (2021-2032)
  3. 6.3 Global Drug Carcinogenicity Testing Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Inotiv
  2. 7.1.1 Inotiv Company Information
  3. 7.1.2 Inotiv Business Overview
  4. 7.1.3 Inotiv Drug Carcinogenicity Testing Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Inotiv Drug Carcinogenicity Testing Product Portfolio
  6. 7.1.5 Inotiv Recent Developments
  7. 7.2 Charles River Laboratories
  8. 7.2.1 Charles River Laboratories Company Information
  9. 7.2.2 Charles River Laboratories Business Overview
  10. 7.2.3 Charles River Laboratories Drug Carcinogenicity Testing Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Charles River Laboratories Drug Carcinogenicity Testing Product Portfolio
  12. 7.2.5 Charles River Laboratories Recent Developments
  13. 7.3 Creative Biolabs
  14. 7.3.1 Creative Biolabs Company Information
  15. 7.3.2 Creative Biolabs Business Overview
  16. 7.3.3 Creative Biolabs Drug Carcinogenicity Testing Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Creative Biolabs Drug Carcinogenicity Testing Product Portfolio
  18. 7.3.5 Creative Biolabs Recent Developments
  19. 7.4 Vivotecnia
  20. 7.4.1 Vivotecnia Company Information
  21. 7.4.2 Vivotecnia Business Overview
  22. 7.4.3 Vivotecnia Drug Carcinogenicity Testing Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Vivotecnia Drug Carcinogenicity Testing Product Portfolio
  24. 7.4.5 Vivotecnia Recent Developments
  25. 7.5 Aurigene Pharmaceutical Services
  26. 7.5.1 Aurigene Pharmaceutical Services Company Information
  27. 7.5.2 Aurigene Pharmaceutical Services Business Overview
  28. 7.5.3 Aurigene Pharmaceutical Services Drug Carcinogenicity Testing Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Aurigene Pharmaceutical Services Drug Carcinogenicity Testing Product Portfolio
  30. 7.5.5 Aurigene Pharmaceutical Services Recent Developments
  31. 7.6 Lhasa Limited
  32. 7.6.1 Lhasa Limited Company Information
  33. 7.6.2 Lhasa Limited Business Overview
  34. 7.6.3 Lhasa Limited Drug Carcinogenicity Testing Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Lhasa Limited Drug Carcinogenicity Testing Product Portfolio
  36. 7.6.5 Lhasa Limited Recent Developments
  37. 7.7 Wako Pure Chemical Industries
  38. 7.7.1 Wako Pure Chemical Industries Company Information
  39. 7.7.2 Wako Pure Chemical Industries Business Overview
  40. 7.7.3 Wako Pure Chemical Industries Drug Carcinogenicity Testing Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Wako Pure Chemical Industries Drug Carcinogenicity Testing Product Portfolio
  42. 7.7.5 Wako Pure Chemical Industries Recent Developments
  43. 7.8 Ichor Life Sciences
  44. 7.8.1 Ichor Life Sciences Company Information
  45. 7.8.2 Ichor Life Sciences Business Overview
  46. 7.8.3 Ichor Life Sciences Drug Carcinogenicity Testing Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Ichor Life Sciences Drug Carcinogenicity Testing Product Portfolio
  48. 7.8.5 Ichor Life Sciences Recent Developments
  49. 7.9 Frontage Labs
  50. 7.9.1 Frontage Labs Company Information
  51. 7.9.2 Frontage Labs Business Overview
  52. 7.9.3 Frontage Labs Drug Carcinogenicity Testing Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Frontage Labs Drug Carcinogenicity Testing Product Portfolio
  54. 7.9.5 Frontage Labs Recent Developments
  55. 7.10 WuXi AppTec
  56. 7.10.1 WuXi AppTec Company Information
  57. 7.10.2 WuXi AppTec Business Overview
  58. 7.10.3 WuXi AppTec Drug Carcinogenicity Testing Revenue and Gross Margin (2021-2026)
  59. 7.10.4 WuXi AppTec Drug Carcinogenicity Testing Product Portfolio
  60. 7.10.5 WuXi AppTec Recent Developments
  61. 7.11 Nanjing Enhancer
  62. 7.11.1 Nanjing Enhancer Company Information
  63. 7.11.2 Nanjing Enhancer Business Overview
  64. 7.11.3 Nanjing Enhancer Drug Carcinogenicity Testing Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Nanjing Enhancer Drug Carcinogenicity Testing Product Portfolio
  66. 7.11.5 Nanjing Enhancer Recent Developments
8 North America
  1. 8.1 North America Drug Carcinogenicity Testing Revenue (2021-2032)
  2. 8.2 North America Drug Carcinogenicity Testing Revenue by Type (2021-2032)
  3. 8.2.1 North America Drug Carcinogenicity Testing Revenue by Type (2021-2026)
  4. 8.2.2 North America Drug Carcinogenicity Testing Revenue by Type (2027-2032)
  5. 8.3 North America Drug Carcinogenicity Testing Revenue Share by Type (2021-2032)
  6. 8.4 North America Drug Carcinogenicity Testing Revenue by Application (2021-2032)
  7. 8.4.1 North America Drug Carcinogenicity Testing Revenue by Application (2021-2026)
  8. 8.4.2 North America Drug Carcinogenicity Testing Revenue by Application (2027-2032)
  9. 8.5 North America Drug Carcinogenicity Testing Revenue Share by Application (2021-2032)
  10. 8.6 North America Drug Carcinogenicity Testing Revenue by Country
  11. 8.6.1 North America Drug Carcinogenicity Testing Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Drug Carcinogenicity Testing Revenue by Country (2021-2026)
  13. 8.6.3 North America Drug Carcinogenicity Testing Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Drug Carcinogenicity Testing Revenue (2021-2032)
  2. 9.2 Europe Drug Carcinogenicity Testing Revenue by Type (2021-2032)
  3. 9.2.1 Europe Drug Carcinogenicity Testing Revenue by Type (2021-2026)
  4. 9.2.2 Europe Drug Carcinogenicity Testing Revenue by Type (2027-2032)
  5. 9.3 Europe Drug Carcinogenicity Testing Revenue Share by Type (2021-2032)
  6. 9.4 Europe Drug Carcinogenicity Testing Revenue by Application (2021-2032)
  7. 9.4.1 Europe Drug Carcinogenicity Testing Revenue by Application (2021-2026)
  8. 9.4.2 Europe Drug Carcinogenicity Testing Revenue by Application (2027-2032)
  9. 9.5 Europe Drug Carcinogenicity Testing Revenue Share by Application (2021-2032)
  10. 9.6 Europe Drug Carcinogenicity Testing Revenue by Country
  11. 9.6.1 Europe Drug Carcinogenicity Testing Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Drug Carcinogenicity Testing Revenue by Country (2021-2026)
  13. 9.6.3 Europe Drug Carcinogenicity Testing Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Drug Carcinogenicity Testing Revenue (2021-2032)
  2. 10.2 China Drug Carcinogenicity Testing Revenue by Type (2021-2032)
  3. 10.2.1 China Drug Carcinogenicity Testing Revenue by Type (2021-2026)
  4. 10.2.2 China Drug Carcinogenicity Testing Revenue by Type (2027-2032)
  5. 10.3 China Drug Carcinogenicity Testing Revenue Share by Type (2021-2032)
  6. 10.4 China Drug Carcinogenicity Testing Revenue by Application (2021-2032)
  7. 10.4.1 China Drug Carcinogenicity Testing Revenue by Application (2021-2026)
  8. 10.4.2 China Drug Carcinogenicity Testing Revenue by Application (2027-2032)
  9. 10.5 China Drug Carcinogenicity Testing Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Drug Carcinogenicity Testing Revenue (2021-2032)
  2. 11.2 Asia Drug Carcinogenicity Testing Revenue by Type (2021-2032)
  3. 11.2.1 Asia Drug Carcinogenicity Testing Revenue by Type (2021-2026)
  4. 11.2.2 Asia Drug Carcinogenicity Testing Revenue by Type (2027-2032)
  5. 11.3 Asia Drug Carcinogenicity Testing Revenue Share by Type (2021-2032)
  6. 11.4 Asia Drug Carcinogenicity Testing Revenue by Application (2021-2032)
  7. 11.4.1 Asia Drug Carcinogenicity Testing Revenue by Application (2021-2026)
  8. 11.4.2 Asia Drug Carcinogenicity Testing Revenue by Application (2027-2032)
  9. 11.5 Asia Drug Carcinogenicity Testing Revenue Share by Application (2021-2032)
  10. 11.6 Asia Drug Carcinogenicity Testing Revenue by Country
  11. 11.6.1 Asia Drug Carcinogenicity Testing Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Drug Carcinogenicity Testing Revenue by Country (2021-2026)
  13. 11.6.3 Asia Drug Carcinogenicity Testing Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Drug Carcinogenicity Testing Revenue (2021-2032)
  2. 12.2 SAMEA Drug Carcinogenicity Testing Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Drug Carcinogenicity Testing Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Drug Carcinogenicity Testing Revenue by Type (2027-2032)
  5. 12.3 SAMEA Drug Carcinogenicity Testing Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Drug Carcinogenicity Testing Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Drug Carcinogenicity Testing Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Drug Carcinogenicity Testing Revenue by Application (2027-2032)
  9. 12.5 SAMEA Drug Carcinogenicity Testing Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Drug Carcinogenicity Testing Revenue by Country
  11. 12.6.1 SAMEA Drug Carcinogenicity Testing Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Drug Carcinogenicity Testing Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Drug Carcinogenicity Testing Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst